Published in FASEB J on November 12, 2007
5-lipoxygenase as an endogenous modulator of amyloid β formation in vivo. Ann Neurol (2010) 2.06
Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J Histochem Cytochem (2008) 1.68
5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol (2012) 1.31
Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase. Am J Pathol (2011) 1.28
Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. Mol Neurodegener (2012) 1.22
Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease. Curr Alzheimer Res (2010) 1.18
Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol (2010) 1.18
Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids (2009) 1.15
Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. Nat Commun (2015) 1.10
Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease. Mol Psychiatry (2013) 1.09
Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Exp Gerontol (2009) 1.05
Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles. PLoS One (2013) 1.05
Mammalian lipoxygenases and their biological relevance. Biochim Biophys Acta (2014) 1.04
Effect of aging on 5-hydroxymethylcytosine in the mouse hippocampus. Restor Neurol Neurosci (2012) 1.02
Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease. J Neurosci (2013) 1.00
Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin. Genes Nutr (2009) 0.99
Amyloid-beta42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. Proc Natl Acad Sci U S A (2009) 0.96
Effects of MK-886, a 5-lipoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of mice. Neurosci Lett (2008) 0.95
Transcriptional regulation of β-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. Ann Neurol (2012) 0.95
Dipetalodipin, a novel multifunctional salivary lipocalin that inhibits platelet aggregation, vasoconstriction, and angiogenesis through unique binding specificity for TXA2, PGF2alpha, and 15(S)-HETE. J Biol Chem (2010) 0.95
Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease. FASEB J (2010) 0.94
5-Lipoxygenase DNA methylation and mRNA content in the brain and heart of young and old mice. Neural Plast (2009) 0.92
Involvement of 5-lipoxygenase in the corticosteroid-dependent amyloid beta formation: in vitro and in vivo evidence. PLoS One (2011) 0.90
Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARβ/δ: a potential therapeutic role for CNS autoimmune disease. Cell Death Dis (2013) 0.90
Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer's disease. Biol Psychiatry (2014) 0.90
The 5-lipoxygenase as a common pathway for pathological brain and vascular aging. Cardiovasc Psychiatry Neurol (2009) 0.90
5-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer's disease. Biol Psychiatry (2013) 0.88
Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's Disease. Front Physiol (2013) 0.88
The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence. Biol Psychiatry (2013) 0.87
5-Lipoxygenase and epigenetic DNA methylation in aging cultures of cerebellar granule cells. Neuroscience (2009) 0.87
Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice. Neurobiol Aging (2014) 0.87
5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5. Neurobiol Aging (2013) 0.86
Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. J Neuroinflammation (2012) 0.85
Restoration of lipoxin A4 signaling reduces Alzheimer's disease-like pathology in the 3xTg-AD mouse model. J Alzheimers Dis (2015) 0.85
5-Lipoxygenase in the Prefrontal Cortex of Suicide Victims. Open Neuropsychopharmacol J (2008) 0.84
Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.84
Modulation of lipopolysaccharide-induced memory insult, γ-secretase, and neuroinflammation in triple transgenic mice by 5-lipoxygenase. Neurobiol Aging (2013) 0.84
Effects of minocycline on cocaine sensitization and phosphorylation of GluR1 receptors in 5-lipoxygenase deficient mice. Neuropharmacology (2010) 0.83
Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg mice. Aging Cell (2013) 0.83
Novel lipid signaling pathways in Alzheimer's disease pathogenesis. Biochem Pharmacol (2013) 0.83
Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. Curr Med Chem (2015) 0.81
Severe In vivo hyper-homocysteinemia is not associatedwith elevation of amyloid-beta peptides in the Tg2576 mice. J Alzheimers Dis (2010) 0.78
The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. Front Cell Neurosci (2015) 0.78
Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer's phenotype. Sci Rep (2017) 0.77
Regulation of gamma-secretase activating protein by the 5Lipoxygenase: in vitro and in vivo evidence. Sci Rep (2015) 0.77
Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors. Sci Rep (2015) 0.77
Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis. Mol Neurobiol (2015) 0.77
Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability. Neuroscience (2012) 0.77
Benefits of neuropsychiatric phenomics: example of the 5-lipoxygenase-leptin-Alzheimer connection. Cardiovasc Psychiatry Neurol (2010) 0.77
Lipoxygenases and poly(ADP-ribose) polymerase in amyloid beta cytotoxicity. Neurochem Res (2011) 0.77
Clitoria ternatea ameliorated the intracerebroventricularly injected streptozotocin induced cognitive impairment in rats: behavioral and biochemical evidence. Psychopharmacology (Berl) (2013) 0.76
Multi-targeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases. J Med Chem (2017) 0.75
The 5-Lipoxygenase as modulator of Alzheimer's γ-secretase and therapeutic target. Brain Res Bull (2016) 0.75
5-lipoxygenase-activating protein as a modulator of olanzapine-induced lipid accumulation in adipocyte. J Lipids (2013) 0.75
The Lipoxygenases: Their Regulation and Implication in Alzheimer's Disease. Neurochem Res (2015) 0.75
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (2001) 11.23
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron (1994) 6.41
Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med (2006) 6.15
An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science (1994) 5.10
Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron (2003) 4.11
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med (2005) 4.00
Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron (2005) 3.72
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest (2003) 3.50
Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci (2001) 2.89
Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci (2002) 2.80
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet (1999) 2.37
Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature (1994) 2.37
Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J (1998) 1.89
Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci (2005) 1.89
The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol Aging (2006) 1.82
12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol (2004) 1.71
Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest (2002) 1.51
Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J (2003) 1.47
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol (2004) 1.47
Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling. J Neurochem (1996) 1.28
Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J (1998) 1.23
Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol (2005) 1.23
Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest (2003) 1.19
5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer's disease. J Neuropsychiatry Clin Neurosci (2001) 1.18
DAPT-induced intracellular accumulations of longer amyloid beta-proteins: further implications for the mechanism of intramembrane cleavage by gamma-secretase. Biochemistry (2006) 1.12
Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol Aging (2001) 1.07
Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats. Life Sci (2006) 0.95
Inflammatory 5-LOX mRNA and protein are increased in brain of aging rats. Neurobiol Aging (2000) 0.94
Coxibs and Alzheimer's disease: should they stay or should they go? Ann Neurol (2006) 0.94
Eicosanoids in synaptic transmission. Crit Rev Neurobiol (1994) 0.92
Cell type-dependent activation of 5-lipoxygenase by arachidonic acid. J Leukoc Biol (2003) 0.87
Cysteinyl-leukotriene production during limbic seizures triggered by kainic acid. Brain Res (1990) 0.83
Leukotrienes and the brain. Lancet (1998) 0.80
Early upregulation of hippocampal 5-lipoxygenase following systemic administration of kainate to rats. Restor Neurol Neurosci (1998) 0.80
A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J (2002) 3.87
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci (2002) 2.80
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol (2010) 2.42
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
5-lipoxygenase as an endogenous modulator of amyloid β formation in vivo. Ann Neurol (2010) 2.06
Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res (2009) 1.88
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron (2013) 1.87
Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.85
The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol Aging (2006) 1.82
Hyperhomocysteinemia impairs endothelium-derived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta synthase-deficient mice. Blood (2011) 1.77
COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res (2003) 1.72
Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation (2004) 1.70
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci (2009) 1.59
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J (2003) 1.47
Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus. Blood (2010) 1.47
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol (2004) 1.47
Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor. J Biol Chem (2007) 1.44
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci (2004) 1.43
Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis (2002) 1.42
Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci (2006) 1.38
Antioxidants for Alzheimer disease. JAMA Neurol (2013) 1.38
MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med (2004) 1.37
Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med (2003) 1.35
Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation (2002) 1.34
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res (2008) 1.32
5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol (2012) 1.31
Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J (2005) 1.30
Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase. Am J Pathol (2011) 1.28
Immunization delays the onset of prion disease in mice. Am J Pathol (2002) 1.26
Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase. Biol Psychiatry (2010) 1.25
Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol Dis (2002) 1.24
Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol (2005) 1.23
Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci (2006) 1.22
An aggregation-specific enzyme-linked immunosorbent assay: detection of conformational differences between recombinant PrP protein dimers and PrP(Sc) aggregates. J Virol (2005) 1.22
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Copper chelation delays the onset of prion disease. J Biol Chem (2003) 1.17
Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol (2007) 1.15
Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem (2002) 1.14
Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer's disease. J Alzheimers Dis (2012) 1.13
A role for 12/15 lipoxygenase in the amyloid beta precursor protein metabolism. J Neurochem (2007) 1.13
Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J Alzheimers Dis (2001) 1.11
Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain. Brain Res (2004) 1.11
Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroinflammation (2004) 1.10
Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J Neurochem (2004) 1.10
Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci (2011) 1.09
Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett (2003) 1.09
Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res (2004) 1.08
Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol (2002) 1.07
Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One (2010) 1.07
A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging (2007) 1.06
CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol (2007) 1.06
Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Exp Gerontol (2009) 1.05
Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles. PLoS One (2013) 1.05
Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol (2012) 1.02
Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. J Pathol (2004) 1.01
Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. J Neuropathol Exp Neurol (2006) 1.01
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol (2008) 1.00
Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis (2009) 1.00
Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency. Arterioscler Thromb Vasc Biol (2010) 0.99
Accelerated prion disease pathogenesis in Toll-like receptor 4 signaling-mutant mice. J Virol (2008) 0.99
Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage (2011) 0.98
Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease. J Virol (2005) 0.95
Absence of 12/15 lipoxygenase reduces brain oxidative stress in apolipoprotein E-deficient mice. Am J Pathol (2005) 0.95
Transcriptional regulation of β-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. Ann Neurol (2012) 0.95
Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J Alzheimers Dis (2011) 0.94
Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease. FASEB J (2010) 0.94
Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol (2006) 0.94
Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J Neuropathol Exp Neurol (2004) 0.94
Coxibs and Alzheimer's disease: should they stay or should they go? Ann Neurol (2006) 0.94
Infectivity of amyloid diseases. Trends Mol Med (2002) 0.93
A safer vaccine for Alzheimer's disease? Neurobiol Aging (2002) 0.93
Apolipoprotein e: essential catalyst of the Alzheimer amyloid cascade. Int J Alzheimers Dis (2012) 0.93
Notch signaling proteins HES-1 and Hey-1 bind to insulin degrading enzyme (IDE) proximal promoter and repress its transcription and activity: implications for cellular Aβ metabolism. Biochim Biophys Acta (2011) 0.93
Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci Lett (2006) 0.92
The innate immune system in Alzheimer's disease. Int J Cell Biol (2013) 0.92
Deletion of the high-density lipoprotein receptor scavenger receptor BI in mice modulates thrombosis susceptibility and indirectly affects platelet function by elevation of plasma free cholesterol. Arterioscler Thromb Vasc Biol (2010) 0.92
Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2alpha-III: evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation (2005) 0.92
Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. Arterioscler Thromb Vasc Biol (2007) 0.91
Targeting prion amyloid deposits in vivo. J Neuropathol Exp Neurol (2004) 0.91
Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. Atherosclerosis (2005) 0.91
Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res (2005) 0.91
Involvement of 5-lipoxygenase in the corticosteroid-dependent amyloid beta formation: in vitro and in vivo evidence. PLoS One (2011) 0.90
Disease modifying approaches for Alzheimer's pathology. Curr Pharm Des (2007) 0.90
Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions. Circulation (2003) 0.90
12/15-Lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. Prostaglandins Other Lipid Mediat (2005) 0.90
Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives. Vaccine (2008) 0.90
Stereological study of the neuronal number and volume of 38 brain subdivisions of subjects diagnosed with autism reveals significant alterations restricted to the striatum, amygdala and cerebellum. Acta Neuropathol Commun (2014) 0.90
The 5-lipoxygenase as a common pathway for pathological brain and vascular aging. Cardiovasc Psychiatry Neurol (2009) 0.90
Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann Neurol (2014) 0.89
The involvement of 5-lipoxygenase activating protein in anxiety-like behavior. J Psychiatr Res (2013) 0.89
Epitope scanning reveals gain and loss of strain specific antibody binding epitopes associated with the conversion of normal cellular prion to scrapie prion. J Neurochem (2004) 0.89